R10026 |
Ruxolitinib (INCB018424) |
CAS NO.:941678-49-5Product Name:β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl
|
R10131 |
Momelotinib (CYT387) |
Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 1
|
R10372 |
Baricitinib (INCB28050, LY3009104) |
Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with
|
R10374 |
Ruxolitinib phosphate;INCB018424 phosphate |
Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to ent
|
R10494 |
Tasocitinib; CP-690550 |
Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1
|
R10536 |
Tofacitinib citrate (Tasocitinib citrate; CP-690550 citrate) |
Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM i
|
R10568 |
Fedratinib; TG101348 |
Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3
|
R10673 |
NSC 42834;JAK2 Inhibitor V; Z3 |
Z3 is a novel specific inhibitor of Jak2 tyrosine kinase.
|
R10709 |
JANEX-1 (Synonyms: WHI-P131; Jak3 inhibitor I) |
Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific i
|
R10710 |
WHI-P180 |
WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with
|
R10766 |
SC-202671 |
JNK inhibitor IX is a selective and potent JNK inhibitor with pIC50 of 6.5 and 6
|
R10903 |
CEP-33779 |
CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-
|
R11000 |
Baricitinib phosphate;LY3009104 phosphate; INCB028050 phosphate |
Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with
|
R11001 |
LY2784544 |
Gandotinib (LY2784544) is a potent JAK2 inhibitor withIC50 of 3 n
|
R11471 |
GLPG0634 analog |
GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 n
|